Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results.
The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales growth of 7% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.